Prohost Biotech – Exclusive Biotech Research – A Comprehensive Resource for Biotech News

Jazz Pharmaceuticals has good, not bad news

November 9, 2018 0

In today’s news Jazz Pharmaceuticals (JAZZ) announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for the approval of solriamfetol. Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) in development for treatment of excessive daytime sleepiness in adult patients with narcolepsy, obstructive sleep apnea, and Parkinson’s disease. In 2014, Jazz Pharmaceuticals acquired a license to develop and commercialize solriamfetol from Aerial …

RegenxBio: Another licensing agreement providing additional validation of its NAV...

About Illumina’s acquisition

Observing Array Biopharma

Alleviating osteoarthritis pain without the need for opioid drugs

Amgen’s product Amgevita, a biosimilar to adalimumab, will be launched...

$Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated thyroid cancer (DTC) patients$

Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated...

The FDA granted Paratek two important product approvals. One is...

Antisense investigational product demonstrates successful results treating a life-threatening disease...

The medical news of the year comes at the hands...

Exelixis: Health Canada approves Cabometyx in advanced renal cell carcinoma

Viking Therapeutics: VK2809 scores impressive results in non-alcoholic fatty liver...

Argenx’s product, Efgartigimod, demonstrates positive results in primary immune thrombocytopenia

Gilead Sciences: In pursuit of cures for intractable diseases

Amgen and AstraZeneca have in hand a very much needed...

Gilead and Galapagos have good news for patients with severely...

RegenxBio has good news

PTC Therapeutics now with a wealthier pipeline

When all the prophets are taken by surprise

Why Celyad’s stock gained $2.30 today

Today’s Highlights

Excellent news about little known products and Nektar Therapeutics

November 12, 2018 0

The Week in Review, which we will post soon, is going to provide news that cancer …

The molecule that enhanced the T Cells cancer treatment efficacy while preventing autoimmune diseases

November 8, 2018 0

Yesterday, the Stock Market skyrocketed and with it a significant number of Prohost Picks that we …

About Exelixis

November 2, 2018 0

Exelixis (EXEL) provided an update that testified to its solid fundamentals, the growth of its approved …

About the Celyad/Horizon discovery agreement

November 1, 2018 0

Celyad (CYAD) announced an exclusive agreement with Horizon Discovery Group plc, for the use of its shRNA …

Prenatal gene editing has already been performed in laboratory animals

October 26, 2018 0

Although the tests are for the prevention of a life-threatening metabolic disorder, the prenatal animal testing …

Immunotherapy and some other results from ESMO 2018

October 24, 2018 0

IMMUNOTHERAPY The Checkpoint Inhibitors The most revered news was the discovery of the checkpoint proteins on …

Why Portola’s stock decline

October 17, 2018 2

Why Portola’s Stock Decline Everybody interested in Portola (PTLA) knows by now that this firm has managed …

Why VTV Therapeutics’ stock added over 48% to its price before trading hours today

October 17, 2018 0

VTV Therapeutics’ (VTVT) stock price added over 48% before trading hours today. The news that some …

After being approved for Eczema, Regeneron’s and Sanofi’s product, Dupixent, succeeded in treating chronic rhinosinusitis, nasal polyps and asthma.

October 16, 2018 0

In two pivotal Phase 3 placebo-controlled trials Regeneron Pharmaceuticals’ (REGN) and Sanofi’s (SNY) drug, Dupixent® (dupilumab), demonstrated a …

Spark Therapeutics: An encouraging attempt to dethrone enzyme replacement as the standard of care treatment for Pompe Disease.

October 9, 2018 0

On Saturday, October 6, 2018, Spark Therapeutics (ONCE) presented positive data from a preclinical trial with SPK-3006 …

The Week in Review

We call it the bad market

October 30, 2018 0

The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of …

Positive News

October 22, 2018 0

The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-stage …

Outperformance, underperformance and volatility

October 2, 2018 0

The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY …

Three important news

September 25, 2018 0

The Week in Review #30 FROM THE DEPARTED WEEK In the past week, we came across …

What is looking good in the aggressive portfolio

September 10, 2018 0

The Week in Review #29 PROHOST AGGRESSIVE PORTFOLIO - The aggressive portfolio hosts biotech firms with …

Outperforming, favorite, and undervalued biotech firms

September 3, 2018 0

The Week in Review #28 The approval of revolutionary products created by biotech firms with solid …

Bombarding future treatment approaches

August 15, 2018 0

The Week in Review #27 PRIORITY TOPICS: CRISPR GENE EDITING, GENETIC ENGINEERING & ANTISENSE TECHNOLOGY The choice of these …

Stories about research, clinical trials results and an FDA ruling

July 9, 2018 0

The Week in Review #26 IN THE BIOTECH WORLD - RESEARCH - IMPROVING CRISPR GENE EDITING The problem …

Finding reasons for underperforming stocks

July 2, 2018 0

The Week in Review #25 When Stocks Plummet for No Relevant Reasons Sometimes investors need to know …

Our outperforming firms and more

June 25, 2018 0

The Week in Review #24 Biotech Stocks’ Performances, Products on the Move and Biotech Research Biotechnology …

Prohost Letters

Following the Stars. Less Science and More Logic

October 14, 2018 0

Prohost Letter #424 Following the Stars Less Science and More Logic We reiterate that while a …

Victims of fear and misunderstanding

August 1, 2018 0

ProhostLetter #423 TOMORROW’S THERAPEUTICS TODAY For a more or less fair evaluation of biotechnology and pharmaceutical …

New stock selection and re-evaluation

June 8, 2018 0

Prohost Letter #422 SUMMARY OF THE PAST ISSUE ARTICLE - REVISITING PROMISING FIRMS (PART1) - The …

Revisiting Biotech Companies We Highlighted

May 25, 2018 0

Prohost Letter #421 PRIVATE LESSONS - Stock prices of publicly-traded biotech companies oscillate for the same …

Real Breakthroughs

April 17, 2018 0

Prohost Letter #420 REAL BREAKTHROUGHS - One Has Already Been Used and the Other Has Extraordinary …

The Prohost Portfolio: Updating the Stock Targets

March 15, 2018 0

Prohost Letter #419 RE-EVALUATION ONLY - The Prohost Portfolio comprises biotechnology and biopharmaceutical companies, that we …

Observing Queer Stories

March 2, 2018 0

Prohost Letter #418 Observing Queer Stories PORTOLA - Portola (PTLA) has been granted approval of an …

Private Lessons and More

February 9, 2018 0

Prohost Letter #417 Private Lessons - These lessons are overdue and we had to do this …

The Year in Review Part 2

January 10, 2018 0

Prohost Letter #416 Part 2 2017 - A YEAR OF BREAKTHROUGH TECHNOLOGIES, BREAKTHROUGH PRODUCTS, IMPROVEMENTS ON …

The Year in Review Part 1

December 31, 2017 0

Prohost Letter #416 Part 1 The Year In Review - 2017 Unheard of Programs - AN …